dilip shanghvi

India's largest pharma company, Sun Pharma, has made its biggest overseas acquisition, buying Organon & Co for $11.8 billion. This deal significantly expands Sun Pharma's global presence and product range. It will double the company's revenue and EBITDA. The acquisition positions Sun Pharma as a major player in women's health and biosimilars. This strategic move strengthens Sun Pharma's position in the global pharmaceutical market.

Indian pharmaceutical giant Sun Pharma is set to acquire US-based Organon & Co. for $11.75 billion in an all-cash deal. This landmark acquisition, one of India's largest overseas ventures, will propel Sun Pharma into the top 25 global pharma companies. The move significantly bolsters its presence in women's health and biosimilars, expanding its global reach across 150 countries.

Sun Pharmaceutical Industries Ltd has agreed to acquire US-based Organon & Co for $11.75 billion in an all-cash deal. This significant outbound acquisition is expected to close in early 2027, strengthening Sun Pharma's global presence in women's health and biosimilars.

New Delhi, Jun 6 () Keen on inorganic expansion, Sun Pharma has said it is looking for targets that are "well managed" unlike the acquisition of Ranbaxy which continues to take significant time of the senior management. "We continue to remain opportunistic for acquisitions.

dilip shanghvi, the 59-year-old promoter of Sun Pharma, appears to have overtaken Mukesh Ambani (57) of Reliance Industries Ltd (RIL) as the richest Indian if one goes by the promoter holdings in the listed companies of the two groups.

dilip shanghvi, founder of Sun Pharma, India’s most valuable drug company with a market cap of $31 billion, and the second-richest Indian with a net worth of $22.5 billion (according to Forbes on Wednesday) says “money is transitional”, while his lifestyle continues to be simple, and he still does the same, with the same amount of money.

Wind turbine maker Suzlon Energy has signed definitive agreements with dilip shanghvi Family and Associates (DSA) for equity investments of Rs 1,800 crore.

Following the successful closure of the merger with drug maker Ranbaxy, dilip shanghvi-led Sun Pharma said on Wednesday that it is initiating the integration process, which will make the combined entity the fifth largest generic company in the world with revenues of over $4.5 billion.

Suzlon shares jumped as much as 20%, adding Rs 1,300 crore to its market capitalization on Monday, after pharma baron dilip shanghvi bought a 23% stake in the Tulsi Tanti-promoted firm for Rs 1,800 crore, triggering an open offer.

dilip shanghvi, the 59-year old boss of Sun Pharma, has taken over Mukesh Ambani, the chief of Reliance group as the richest Indian if one goes by the promoter holdings in the listed companies of the two groups.

From assisting his father in the wholesale generic drugs business to starting his own psychiatric drug manufacturing company in 1983 with just a few thousand rupees, and then going on to become the owner of the world’s fifth largest generics player, dilip shanghvi has literally come a long way.

Pharma tycoon dilip shanghvi on Wednesday surpassed Mukesh Ambani as the world's richest Indian with a net worth of $21.5 billion.

dilip shanghvi of Sun Pharmaceuticals, along with proposed partners Telenor and IDFC, has decided not to move ahead on the in-principle approval received for setting up a payments bank. It's the second applicant to bail out. In March, Cholamandalam had said it would not set up a payments bank.

Sun Pharmaceutical Industries chairman and managing director dilip shanghvi was on Monday named Ernst & Young Entrepreneur of the Year 2010. He will represent India at the Ernst & Young World Entrepreneur of the Year Award in Monte Carlo this June.

India’s biggest drug maker Sun Pharma has offered to acquire the outstanding shareholding in its United States-based subsidiary, Taro Pharma for around $300 million through a reverse triangular merger.

Sun Pharma announced on Thursday it will acquire US-based dermatology company DUSA Pharmaceuticals, Inc for $230 million.

Total income of the company increased to Rs 6,768 crore during the first quarter of 2015-16 as against Rs 6,341 crore for the year ago period.

Sun Pharmaceuticals Industries' dilip shanghvi has been named in the list of Asia's top ten wealthiest self-made billionaires, topped by Hong Kong business tycoon Li Ka-Shing, according to Wealth-X.

dilip shanghvi, MD of India’s most valuable drug firm Sun Pharmaceutical Industries and one of the richest first-generation billionaires in the country with a net worth of $7.8 billion, is now looking at new markets to fire the company’s growth engine.

Fresh after a $3.2 billion all-stock deal to acquire Ranbaxy, mired in regulatory troubles, dilip shanghvi, promoter and MD Sun Pharma, admitted in a chat with TOI that there may be challenges going forward.

The Sun Pharmaceutical-Ranbaxy combine, India's largest drugmaker, now has a top-level team in place.

A jury chaired by Microsoft CEO Satya Nadella has chosen Sun Pharma MD dilip shanghvi, who built the country’s biggest pharma company from scratch, as The Economic Times Business Leader of the Year, 2014.

Many would be pleasantly surprised to know that 1981 super hit movie 'Ek Duuje Ke Liye' gave birth to global eye care and research centre L V Prasad Eye Institute in Hyderabad.